Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term eptinezumab in chronic cluster headache
2020-001968-28Phase 3Completed
- Sponsor
- Lundbeck
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eptinezumab in Cluster Headache (CH), sponsored by Lundbeck. Primary endpoint: Number of participants with adverse events. Started May 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on 2020-001968-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001968-28.